Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Document first published:
Page updated:
Topic:
Publication type:

Etanercept and adalimumab are both recommended to be available as routine commissioning treatment options for deficiency of adenosine deaminase type 2 (DADA2) within the criteria set out in these documents.

Document

Clinical commissioning policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Clinical commissioning policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

  • PDF
  • 204 KB
  • 8 pages

Summary

Published 26 February 2025.

Document

Equality and Health Inequalities Impact Assessment (EHIA): Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Equality and Health Inequalities Impact Assessment (EHIA): Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

  • PDF
  • 160 KB
  • 12 pages

Summary

Published 26 February 2025.

Document

Engagement report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Engagement report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

  • PDF
  • 152 KB
  • 5 pages

Summary

Published 26 February 2025.

Document

Clinical panel report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Clinical panel report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

  • PDF
  • 107 KB
  • 3 pages

Summary

Published 26 February 2025.

Document

Clinical Priorities Advisory Group summary report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

Clinical Priorities Advisory Group summary report: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)

  • PDF
  • 387 KB
  • 25 pages

Summary

Published 26 February 2025.

Document

Evidence review: Adalimumab monotherapy for deficiency of adenosine deaminase 2 (DADA2)

Evidence review: Adalimumab monotherapy for deficiency of adenosine deaminase 2 (DADA2)

  • PDF
  • 881 KB
  • 78 pages

Summary

Published 26 February 2025.

Document

Evidence review: Etanercept monotherapy for deficiency of adenosine deaminase 2 (DADA2)

Evidence review: Etanercept monotherapy for deficiency of adenosine deaminase 2 (DADA2)

  • PDF
  • 985 KB
  • 95 pages

Summary

Published 26 February 2025.